T-DXd for HER2-Low BC: Analysis Confirms Adverse Effects

A safety analysis following a randomized phase 3 trial confirms that vomiting and nausea are common in patients who take the drug trastuzumab deruxtecan to treat HER2-low metastatic breast cancer.

Related Keywords

Germany ,California ,United States ,Brazil ,San Francisco ,Daiichi Sankyo ,Roche Genentech ,Tanja Fehm ,Porto Alegre ,Gustavo Werutsky ,Astrazeneca ,Pfizer ,European Society For Medical Oncology Breast Cancer ,University Of California ,Novartis ,Glaxosmithkline ,University Hospital ,Hope Rugo ,European Society ,Medical Oncology Breast Cancer ,New England Journal ,Moinhos De Vento Hospital ,Scorpion Therapeutics ,Taiho Oncology ,Metastatic Breast Carcinoma ,Biologic Therapy ,Breast Cancer ,Alignant Breast Neoplasm ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,Rastuzumab ,Breast ,Nausea ,Cancer ,Alignant Neoplasia ,Arcinoma ,Toxicology ,Targeted Therapy ,Humanized Monoclonal Antibody ,Patient Safety ,Adverse Effects ,Side Effects ,Hint ,